Data collection
Data on patients’ demographics, underlying comorbidities, clinical presentation, oxygen-support requirements and laboratory results were recorded. The time to SARS-CoV-2 RNA clearance in respiratory specimens of patients with confirmed diagnosis were also assessed. Virus clearance was defined as the time from admission until the RT-PCR assay was negative on 2 occasions. To assess Kaletra and interferon alfa-2b safety profile, the occurrence of nausea, diarrhea, rash and serial levels of white blood cell (WBC) count, neutrophil count, hemoglobin, platelet count, aminotransferase, bilirubin, and creatinine kinase were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0..